Amarin (AMRN) Projected to Post Earnings on Wednesday

Amarin (NASDAQ:AMRN) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect Amarin to post earnings of ($0.06) per share and revenue of $50.75 million for the quarter.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($1.20) by ($1.20). Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%. The business had revenue of $62.31 million during the quarter, compared to analysts’ expectations of $32.37 million. On average, analysts expect Amarin to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amarin Trading Down 2.8 %

Amarin stock opened at $10.60 on Tuesday. The firm has a market capitalization of $219.52 million, a P/E ratio of -117.78 and a beta of 0.66. The stock’s fifty day simple moving average is $9.50 and its 200-day simple moving average is $10.33. Amarin has a twelve month low of $7.08 and a twelve month high of $20.60.

Wall Street Analysts Forecast Growth

AMRN has been the subject of several recent research reports. StockNews.com started coverage on Amarin in a research note on Wednesday, April 16th. They issued a “sell” rating for the company. The Goldman Sachs Group lowered their price target on shares of Amarin from $20.00 to $7.00 and set a “sell” rating for the company in a report on Thursday, April 17th.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.